MARKSANS PHARMA LIMITED (MARKSANS)

NSE: ₹239.14
BSE: ₹239.30
Stock Performance
Corporate Announcements
Announcement under Regulation 30 (LODR)-Credit Rating

India Ratings and Research has revised the outlook for the Company's bank loan facilities to Positive from Stable

2026-06-09 15:12:43
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet – Intimation

Intimation of schedule for Virtual Investors Conference

2026-06-08 14:50:27
Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Marksans Pharma Limited submits Transcripts of Investors/Analyst meet on Q4 FY 26 Audited Financial Results

2026-06-03 14:23:23
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication regarding Second 100 day Campaign- "Saksham Niveshak"

2026-06-03 12:52:54
DISCLOSURE REGARDING SECOND 100 DAY CAMPAIGN - "SAKSHAM NIVESHAK"

Campaign for KYC and other related updations and shareholders engagement to prevent transfer of unclaimed dividend to IEPF

2026-06-02 12:42:07
Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release titled Marksans Pharma Ltd. to acquire 100 percent of Netherland based QliniQ B.V., strengthening presence in European Markets

2026-06-01 08:57:48
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet – Outcome

Audio Recording of investor(s) / analyst(s) meet Conference Call on Q4 FY26 Financial Results

2026-05-27 18:52:29
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication of Audited Financial Results for the financial year ended 31 March, 2026

2026-05-27 17:56:22
Compliances-Reg.24(A)-Annual Secretarial Compliance

ASCR under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year 31, March 2026

2026-05-27 17:36:03
Corporate Action-Board approves Dividend

The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting

2026-05-26 13:34:34

Quarterly Financials

Consolidated Standalone
Particulars Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Revenue from Operations 182.04 204.67 241.36 225.20 254.53 308.63 311.87 299.36 319.73 320.44 339.73 361.57
YOY Revenue Growth % 14.38% 20.21% 39.72% 47.14% 39.82% 50.79% 29.21% 32.93% 25.62% 3.83% 8.93% 20.78%
Other Income 32.62 15.93 1.33 12.19 8.15 31.36 22.51 7.82 2.01 58.19 15.86 27.48
Total Income 214.66 220.60 242.69 237.39 262.68 339.98 334.37 307.17 321.74 378.63 355.59 389.05
Total Expenses + 160.27 176.10 208.09 198.99 220.38 263.65 259.65 257.27 258.17 257.14 273.47 264.69
Cost of Materials Consumed 82.80 102.83 117.16 104.36 116.12 134.73 141.27 145.06 145.28 146.66 151.00 159.48
Employee Benefit Expense 16.93 18.23 20.47 21.56 23.19 23.91 25.75 28.82 27.90 28.46 32.70 32.92
Other Expenses 34.35 34.65 41.11 47.11 49.65 67.29 55.94 55.84 56.99 54.43 58.38 47.34
Operating Profit 21.77 28.57 33.27 26.21 34.15 44.98 52.21 42.09 61.56 63.30 66.26 96.88
OPM % 12% 14% 13.8% 11.6% 13.4% 14.6% 16.7% 14.1% 19.3% 19.8% 19.5% 26.8%
Profit Before Tax + 54.40 44.50 34.60 38.40 42.30 76.34 74.72 49.90 63.57 121.49 82.12 124.36
Tax Expense 10.20 13.21 9.31 5.41 10.28 13.13 19.26 12.31 15.52 21.69 21.20 32.44
Tax % 18.8% 29.7% 26.9% 14.1% 24.3% 17.2% 25.8% 24.7% 24.4% 17.9% 25.8% 26.1%
Profit After Tax 44.19 31.29 25.29 32.99 32.02 63.20 55.46 37.59 48.06 99.81 60.91 91.92
EPS (Basic) 0.98 0.69 0.56 0.73 0.71 1.39 1.22 0.83 1.06 2.20 1.34 2.03

Yearly Financial Results

Consolidated Standalone
Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Revenue from Operations 1,341.48 1,174.37 853.27 655.20 658.29 599.55 433.42
YOY Revenue Growth % 14.23% 37.63% 30.23% -0.47% 9.8% 38.33% -
Other Income 103.53 69.83 62.07 60.48 42.25 31.16 0.17
Total Income 1,445.01 1,244.21 915.35 715.69 700.54 630.70 433.59
Total Expenses + 1,053.47 1,000.95 743.45 583.65 566.03 506.37 328.10
Cost of Materials Consumed 602.43 537.18 407.15 338.49 327.99 291.29 209.20
Employee Benefit Expense 121.98 101.68 77.19 56.09 60.46 54.64 48.51
Other Expenses 217.15 228.71 157.21 112.76 106.52 93.28 70.39
Operating Profit 288.01 173.43 109.82 71.55 92.26 93.17 105.32
OPM % 21.5% 14.8% 12.9% 10.9% 14% 15.5% 24.3%
Profit Before Exceptional 391.54 243.26 171.89 132.04 134.51 124.33 52.73
Exceptional Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Profit Before Tax + 391.54 243.26 171.89 132.04 134.51 124.33 52.73
Tax Expense 90.85 54.99 38.13 29.17 30.52 25.95 14.82
Tax % 23.2% 22.6% 22.2% 22.1% 22.7% 20.9% 28.1%
Profit After Tax 300.70 188.27 133.76 102.87 103.99 98.38 37.90
EPS (Basic) 6.64 4.15 2.95 2.48 2.54 2.40 0.93

Balance Sheet

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
ASSETS
Non-Current Assets + 684.95 673.08 568.33 431.10 375.75 369.32 0.00
Property, Plant & Equipment 368.68 353.59 268.51 140.88 131.86 110.83 0.00
Capital Work in Progress 0.00 0.00 0.00 3.91 0.00 0.00 0.00
Non-Current Investments 267.21 265.75 265.75 265.75 236.07 236.07 0.00
Goodwill 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Intangible Assets 1.76 29.78 3.07 3.06 3.65 18.26 0.00
Current Assets + 1,309.08 1,082.22 947.70 913.76 589.86 349.24 0.00
Inventories 189.13 205.21 190.85 130.95 103.68 93.69 0.00
Trade Receivables 623.46 549.58 370.17 305.49 246.78 146.79 0.00
Cash and Cash Equivalents 91.25 60.27 41.93 148.31 224.05 105.72 0.00
Current Investments 0.00 0.74 26.99 0.54 0.44 0.00 0.00
LIABILITIES & EQUITY
Total Equity 1,652.31 1,383.49 1,222.71 1,111.32 784.67 599.72 0.00
Equity Share Capital 45.32 45.32 45.32 45.32 40.93 40.93 0.00
Other Equity 1,606.99 1,338.17 1,177.39 1,066.01 743.74 558.79 0.00
Non-Current Liabilities 31.47 26.18 20.90 17.00 14.41 23.94 0.00
Current Liabilities 310.25 345.64 272.44 216.54 166.53 94.90 0.00
Total Liabilities 341.72 371.82 293.33 233.54 180.94 118.84 0.00

Cash Flow Statement

Particulars Mar 2026 Mar 2025 Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020
Cash from Operating Activities 211.09 31.02 34.05 51.73 50.97 107.07 0.00
Cash from Investing Activities -140.29 17.24 -114.22 -194.62 -8.40 8.82 0.00
Cash from Financing Activities -39.23 -29.92 -26.22 210.02 75.86 -13.53 0.00
Net Increase/Decrease in Cash 30.98 18.34 -106.38 67.12 118.44 102.36 0.00